In the field of innovative pharmaceuticals, pharmaceutical fund managers are replicating the NEV industry's experience of deploying in-vehicle chips and avoiding investment in complete vehicles. Recently, the market in the two major experimental animal-related sectors, experimental monkeys and experimental mice, has continued to heat up, and public funds have begun to hold heavy positions or even license these sectors. In particular, upstream R&D service companies are becoming a definitive direction in the eyes of pharmaceutical fund managers due to their rigid demand and cash flow advantages. At the same time, by arranging these directions, pharmaceutical fund managers can also avoid the huge investment and risk of drug development failure often faced by innovative pharmaceutical companies. A number of fund managers stressed that clinical data is becoming a hard standard for testing the value of innovative drug pipelines, and the sector is expected to usher in a new stage of improving both performance and valuation.

In the field of innovative pharmaceuticals, pharmaceutical fund managers are replicating the NEV industry's experience of deploying in-vehicle chips and avoiding investment in complete vehicles. Recently, the market in the two major experimental animal-related sectors, experimental monkeys and experimental mice, has continued to heat up, and public funds have begun to hold heavy positions or even license these sectors. In particular, upstream R&D service companies are becoming a definitive direction in the eyes of pharmaceutical fund managers due to their rigid demand and cash flow advantages. At the same time, by arranging these directions, pharmaceutical fund managers can also avoid the huge investment and risk of drug development failure often faced by innovative pharmaceutical companies. A number of fund managers stressed that clinical data is becoming a hard standard for testing the value of innovative drug pipelines, and the sector is expected to usher in a new stage of improving both performance and valuation.